{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:23:18Z","timestamp":1788546198002,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The First-Class Discipline Team of Kunming Medical University","award":["No. 2024XKTDPY21"],"award-info":[{"award-number":["No. 2024XKTDPY21"]}]},{"name":"The First-Class Discipline Team of Kunming Medical University","award":["No. 2024XKTDPY21"],"award-info":[{"award-number":["No. 2024XKTDPY21"]}]},{"name":"The First-Class Discipline Team of Kunming Medical University","award":["No. 2024XKTDPY21"],"award-info":[{"award-number":["No. 2024XKTDPY21"]}]},{"name":"Research Project on Education and Teaching of Kunming Medical University, 2023","award":["Project No. 2023-JY-Y-090"],"award-info":[{"award-number":["Project No. 2023-JY-Y-090"]}]},{"name":"Undergraduate Teaching Quality and Reform Project of Kunming Medical University, 2024","award":["Project No. 2024KCSZSFXM022"],"award-info":[{"award-number":["Project No. 2024KCSZSFXM022"]}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","award":["2025J0227"],"award-info":[{"award-number":["2025J0227"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","award":["2025J0227"],"award-info":[{"award-number":["2025J0227"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","award":["2025J0227"],"award-info":[{"award-number":["2025J0227"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10858-x","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:59:16Z","timestamp":1745596756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["INSTIs-centered antiviral regimens for first-line treatment of HIV\/AIDS: a network meta-analysis and cost-effectiveness analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"10858_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 2022 fact sheet. https:\/\/www.unaids.org\/en\/resources\/fact-sheet (accessed 15 December 2023)."},{"key":"10858_CR2","unstructured":"National Health Commission of the People\u2019s Republic of China. China health statistical yearbook 2022. http:\/\/www.nhc.gov.cn\/ (accessed 15 December 2023)."},{"key":"10858_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(07)60315-8","volume":"369","author":"Z Wu","year":"2007","unstructured":"Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China\u2019s response to HIV\/AIDS. Lancet. 2007;369:679\u201390.","journal-title":"Lancet"},{"key":"10858_CR4","unstructured":"National Health Commission of the People\u2019s Republic of China. The 13th five-year action plan for HIV\/AIDS prevention and control. http:\/\/www.nhc.gov.cn\/ (accessed 15 December 2023)."},{"key":"10858_CR5","first-page":"602","volume":"145","author":"F Zhang","year":"2006","unstructured":"Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2006;145:602\u201312.","journal-title":"Ann Intern Med"},{"key":"10858_CR6","first-page":"966","volume":"339","author":"F Tanser","year":"2013","unstructured":"Tanser F, B\u00e4rnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal. South Africa Science. 2013;339:966\u201371.","journal-title":"South Africa Science"},{"key":"10858_CR7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40249-019-0618-5","volume":"9","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Sun X, He Y, et al. Economic burden of HIV and TB co-infection in a rural county in China. Infect Dis Poverty. 2020;9:2.","journal-title":"Infect Dis Poverty"},{"key":"10858_CR8","unstructured":"Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/guidelines-use-antiretroviral-agents-adults-and-adolescents-living (accessed 15 December 2023)."},{"key":"10858_CR9","doi-asserted-by":"publisher","unstructured":"Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8(2):e55312. https:\/\/doi.org\/10.1371\/journal.pone.0055312.","DOI":"10.1371\/journal.pone.0055312"},{"key":"10858_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1086\/649214","volume":"50","author":"RP Walensky","year":"2010","unstructured":"Walensky RP, Kuritzkes DR. The impact of the President\u2019s Emergency Plan for AIDS Relief (PEPFAR) beyond HIV and why it remains essential. Clin Infect Dis. 2010;50:272\u20135.","journal-title":"Clin Infect Dis"},{"key":"10858_CR11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12879-019-3708-x","volume":"19","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li X, Wan Z, et al. Cost-effectiveness analysis of early versus delayed antiretroviral therapy in treatment-naive HIV-infected patients in China. BMC Infect Dis. 2019;19:64.","journal-title":"BMC Infect Dis"},{"key":"10858_CR12","first-page":"667","volume":"26","author":"X Li","year":"2012","unstructured":"Li X, Lu H, Raymond HF, et al. Untangling the socioeconomic correlates of HIV infection in China\u2019s MSM population: a pathway analysis framework. AIDS. 2012;26:667\u201375.","journal-title":"AIDS"},{"key":"10858_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","volume":"374","author":"JL Lennox","year":"2009","unstructured":"Lennox JL, DeJesus E, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet. 2009;374:796\u2013806.","journal-title":"Lancet"},{"key":"10858_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"MA Boyd","year":"2019","unstructured":"Boyd MA, Donovan B, Phanuphak P, et al. Efficacy and safety of dolutegravir\u2013abacavir\u2013lamivudine versus efavirenz\u2013emtricitabine\u2013tenofovir in antiretroviral therapy-naive adults with HIV-1 infection: week 48 results from the international randomized double-blind placebo-controlled GEMINI 1 and 2 studies. Lancet. 2019;393:143\u201355.","journal-title":"Lancet"},{"key":"10858_CR15","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial HIV-1 therapy: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2015;385:2606\u201315.","journal-title":"Lancet"},{"key":"10858_CR16","doi-asserted-by":"publisher","unstructured":"Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, Fox MP, Wood R, Prozesky H, Giddy J, Garone DB, Cornell M, Egger M, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10(4):e1001418. https:\/\/doi.org\/10.1371\/journal.pmed.1001418.","DOI":"10.1371\/journal.pmed.1001418"},{"key":"10858_CR17","first-page":"132","volume":"51","author":"VC Marconi","year":"2010","unstructured":"Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal. South Africa Clin Infect Dis. 2010;51:132\u201340.","journal-title":"South Africa Clin Infect Dis"},{"key":"10858_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1524-4733.2008.00326.x","volume":"11","author":"TL Kauf","year":"2008","unstructured":"Kauf TL, Roskell N, Shearer A, Gazzard B, Mauskopf J, Davis EA, Nimsch C. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008;11:1144\u201353.","journal-title":"Value Health"},{"key":"10858_CR19","first-page":"105","volume":"28","author":"WS Yang","year":"2019","unstructured":"Yang WS, L\u00fc JN. Survey and analysis of the use of free antiretroviral drugs for AIDS in Beihai City from 2014 to 2018. Chin J Pharm. 2019;28:105\u20137.","journal-title":"Chin J Pharm"},{"issue":"1","key":"10858_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12913-020-05687-4","volume":"20","author":"X Zhuang","year":"2020","unstructured":"Zhuang X, Chen Y, Wu Z, et al. Analysis of hospitalization expenses of 610 HIV\/AIDS patients in Nantong, China. BMC Health Serv Res. 2020;20(1):813. https:\/\/doi.org\/10.1186\/s12913-020-05687-4.","journal-title":"BMC Health Serv Res"},{"key":"10858_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59: 101991. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101991.","journal-title":"EClinicalMedicine"},{"key":"10858_CR22","first-page":"1394","volume":"43","author":"DD Niu","year":"2022","unstructured":"Niu DD, Tang HL, Chen FF, Xiao TC, Chen C, Liu H, Lyu P. Multi-state Markov model analysis of disease outcomes and influencing factors in HIV infected individuals receiving antiretroviral therapy in Luzhou of Sichuan province 2010\u20132021. Zhonghua Liu Xing Bing Xue Za Zhi. 2022;43:1394\u2013400.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"10858_CR23","doi-asserted-by":"publisher","unstructured":"Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389\u2013e400. https:\/\/doi.org\/10.1016\/S2352-3018(20)30099-0.","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"10858_CR24","doi-asserted-by":"publisher","unstructured":"Avihingsanon A, Lu H, Leong CL, Hung CC, Koenig E, Kiertiburanakul S, Lee MP, Supparatpinyo K, Zhang F, Rahman S, D'Antoni ML, Wang H, Hindman JT, Martin H, Baeten JM, Li T; ALLIANCE Study Team. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023;10(10):e640\u2013e652. https:\/\/doi.org\/10.1016\/S2352-3018(23)00151-0.","DOI":"10.1016\/S2352-3018(23)00151-0"},{"key":"10858_CR25","doi-asserted-by":"publisher","unstructured":"Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154\u2013e160. https:\/\/doi.org\/10.1016\/S2352-3018(17)30016-4.","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"10858_CR26","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1097\/QAD.0000000000001894","volume":"32","author":"PE Sax","year":"2018","unstructured":"Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Coformulated bictegravir emtricitabine tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine\/tenofovir alafenamide. AIDS. 2018;32:1723\u20135.","journal-title":"AIDS"},{"key":"10858_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","volume":"46","author":"M Markowitz","year":"2007","unstructured":"Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125\u201333.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10858_CR28","volume":"36","author":"B Su","year":"2023","unstructured":"Su B, Gao G, Wang M, Lu Y, Li L, Chen C, et al. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine\/tenofovir disoproxil fumarate for medication of treatment-na\u00efve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. Lancet Reg Health West Pac. 2023;36: 100769.","journal-title":"Lancet Reg Health West Pac"},{"key":"10858_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.569766","volume":"11","author":"PL Guo","year":"2020","unstructured":"Guo PL, He HL, Chen XJ, Chen JF, Chen XT, Lan Y, et al. Antiretroviral long-term efficacy and resistance of Lopinavir\/Ritonavir plus Lamivudine in HIV-1-infected treatment-na\u00efve patients (ALTERLL): 144-week results of a randomized open-label non-inferiority study from Guangdong. China Front Pharmacol. 2020;11: 569766.","journal-title":"China Front Pharmacol"},{"key":"10858_CR30","doi-asserted-by":"publisher","unstructured":"Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord; Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Mu\u00f1oz J, Kjaer J, Grarup J, Ch\u00eane G, Bucher H. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194. https:\/\/doi.org\/10.1371\/journal.pmed.1001194.","DOI":"10.1371\/journal.pmed.1001194"},{"key":"10858_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","volume":"52","author":"M Markowitz","year":"2009","unstructured":"Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52:350\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10858_CR32","first-page":"92","volume":"28","author":"YF Qiu","year":"2022","unstructured":"Qiu YF, Wu SL, Xia PC, Wang ZH, Zhang CY, Xie MR. Analysis of survival status and influencing factors of adult AIDS patients receiving antiretroviral therapy in Fujian Province from 2004 to 2020. Chin J AIDS STD. 2022;28:92\u20136.","journal-title":"Chin J AIDS STD"},{"key":"10858_CR33","first-page":"925","volume":"16","author":"Y Chen","year":"2017","unstructured":"Chen Y, Shen LM, Li Y, Li JL, Huang L, An Z, et al. Analysis of survival factors of AIDS patients receiving antiretroviral therapy in Guizhou Province. Chin J Infect Control. 2017;16:925\u201330.","journal-title":"Chin J Infect Control"},{"key":"10858_CR34","first-page":"805","volume":"48","author":"ML Wei","year":"2023","unstructured":"Wei ML, Xiang X, Zhou C, Wu GH, Yan B. Survival analysis of patients receiving antiretroviral therapy in the comprehensive AIDS prevention and control demonstration area in Chongqing from 2016 to 2021. J Chongqing Med Univ. 2023;48:805\u201310.","journal-title":"J Chongqing Med Univ"},{"key":"10858_CR35","volume-title":"A guide to the evaluation of pharmacoeconomics in China 2022","author":"GE Liu","year":"2022","unstructured":"Liu GE. A guide to the evaluation of pharmacoeconomics in China 2022. Beijing: China Market Press; 2022."},{"issue":"1","key":"10858_CR36","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1186\/s12889-024-20857-3","volume":"24","author":"RQ Fan","year":"2024","unstructured":"Fan RQ, Shu JT, Huang H, Shi LY, Ge QW, Zhuang X, Zou MY, Qin G. Economic evaluation of short message service intervention for HIV prevention among men who have sex with men in China: A modelling study. BMC Public Health. 2024;24(1):3553. https:\/\/doi.org\/10.1186\/s12889-024-20857-3.","journal-title":"BMC Public Health"},{"key":"10858_CR37","unstructured":"Yaozhi Database. Comprehensive drug price inquiry platform. 2024. Available from: https:\/\/db.yaozh.com\/?ga_source=www&ga_name=home_drop-down_nav."},{"issue":"1","key":"10858_CR38","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1186\/s12889-023-17052-1","volume":"23","author":"M Li","year":"2023","unstructured":"Li M, Cao Y, Huang H, Qin G, Chu M, Zou M, Zhuang X. Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China. BMC Public Health. 2023;23(1):2228. https:\/\/doi.org\/10.1186\/s12889-023-17052-1.","journal-title":"BMC Public Health"},{"key":"10858_CR39","unstructured":"National Bureau of Statistics of China. China Statistical Yearbook 2023: Total wages of employees in urban non-private units by industry (4\u20138). 2023. Available from: https:\/\/www.stats.gov.cn\/sj\/ndsj\/2023\/indexch.htm."},{"key":"10858_CR40","unstructured":"CEIC Data. (2024). China Consumer Price Index (CPI) growth. Retrieved from https:\/\/www.ceicdata.com\/en\/indicator\/china\/consumer-price-index-cpi-growth"},{"issue":"6","key":"10858_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107164","volume":"63","author":"C Hidalgo-Tenorio","year":"2024","unstructured":"Hidalgo-Tenorio C, Sequera S, Vivancos MJ, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial. Int J Antimicrob Agents. 2024;63(6): 107164. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107164.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10858_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","volume":"25","author":"J Kazibwe","year":"2022","unstructured":"Kazibwe J, Gheorghe A, Wilson D, et al. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: A review. Value in Health. 2022;25(3):385\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.08.014.","journal-title":"Value in Health"},{"key":"10858_CR43","unstructured":"TreeAge Software, Inc. TreeAge Pro User Manual: Version 2021. 2021. Available from: https:\/\/www.treeage.com\/."},{"key":"10858_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1574","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Statement: Updated Guidelines for Health Economic Evaluations. BMJ. 2022;376: n1574. https:\/\/doi.org\/10.1136\/bmj.n1574.","journal-title":"BMJ"},{"key":"10858_CR45","first-page":"39","volume":"10","author":"XP Dong","year":"2008","unstructured":"Dong XP, Zhou F, Zhang L, Zhao XP, Li H, Cao YZ. Direct cost analysis of antiretroviral therapy for AIDS in rural areas. Chin Health Econ. 2008;10:39\u201341.","journal-title":"Chin Health Econ"},{"key":"10858_CR46","unstructured":"Ma L. Research on cost, effect and utility of different antiretroviral treatment strategies for HIV sero-discordant families [D]. Chinese Center for Disease Control and Prevention; 2016."},{"key":"10858_CR47","first-page":"440","volume":"36","author":"XY Zhang","year":"2015","unstructured":"Zhang XY, Li M, Feng YB, Bu K, Fu GF, Liu XY, et al. Analysis of disease burden and influencing factors of AIDS patients receiving antiretroviral therapy in Nanjing. Chin J Epidemiol. 2015;36:440\u20134.","journal-title":"Chin J Epidemiol"},{"key":"10858_CR48","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"S Walmsley","year":"2013","unstructured":"Walmsley S, et al. Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807\u201318.","journal-title":"N Engl J Med"},{"key":"10858_CR49","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1111160","volume":"367","author":"B Clotet","year":"2012","unstructured":"Clotet B, et al. Dolutegravir for the first-line treatment of HIV infection. N Engl J Med. 2012;367:725\u201333.","journal-title":"N Engl J Med"},{"key":"10858_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12879-021-06991-y","volume":"22","author":"L Deng","year":"2022","unstructured":"Deng L, Li C, Chen P, et al. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection. BMC Infect Dis. 2022;22:17. https:\/\/doi.org\/10.1186\/s12879-021-06991-y.","journal-title":"BMC Infect Dis"},{"key":"10858_CR51","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48-week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735\u201343.","journal-title":"Lancet"},{"key":"10858_CR52","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"JM Molina","year":"2014","unstructured":"Molina JM, et al. Once-daily dolutegravir is superior to once-daily darunavir\/ritonavir in treatment-naive HIV-1-positive adults: 48-week results from the FLAMINGO study. Lancet. 2014;383:2222\u201331.","journal-title":"Lancet"},{"key":"10858_CR53","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(13)61221-0.","journal-title":"Lancet"},{"key":"10858_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12879-024-09565-w","volume":"24","author":"K Falasca","year":"2024","unstructured":"Falasca K, Ucciferri C, Di Gasbarro A, et al. Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen. BMC Infect Dis. 2024;24:665. https:\/\/doi.org\/10.1186\/s12879-024-09565-w.","journal-title":"BMC Infect Dis"},{"key":"10858_CR55","first-page":"52","volume":"70","author":"N Clumeck","year":"2015","unstructured":"Clumeck N, et al. Simplification with fixed-dose tenofovir\/emtricitabine\/rilpivirine single-tablet regimen maintains HIV viral suppression and improves renal and bone markers compared with tenofovir\/emtricitabine\/efavirenz: a 96-week, randomized, non-inferiority trial. JAIDS. 2015;70:52\u20138.","journal-title":"JAIDS"},{"key":"10858_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493\u2013505.","journal-title":"N Engl J Med"},{"key":"10858_CR57","doi-asserted-by":"publisher","first-page":"20534","DOI":"10.7448\/IAS.19.1.20504","volume":"19","author":"M Vitoria","year":"2016","unstructured":"Vitoria M, Hill A, Ford N, Doherty M. Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: What more do we need to know? J Int AIDS Soc. 2016;19:20534.","journal-title":"J Int AIDS Soc"},{"key":"10858_CR58","first-page":"1805","volume":"65","author":"VC Marconi","year":"2017","unstructured":"Marconi VC, et al. Impact of integrase inhibitors on HIV resistance and clinical outcomes in resource-limited settings. Clin Infect Dis. 2017;65:1805\u201313.","journal-title":"Clin Infect Dis"},{"key":"10858_CR59","unstructured":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. Geneva: World Health Organization; 2016. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK374294\/."},{"key":"10858_CR60","doi-asserted-by":"crossref","first-page":"20534","DOI":"10.7448\/IAS.19.1.20714","volume":"19","author":"N Ford","year":"2016","unstructured":"Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: What more do we need to know? J Int AIDS Soc. 2016;19:20534.","journal-title":"J Int AIDS Soc"},{"key":"10858_CR61","doi-asserted-by":"publisher","unstructured":"Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, Ford N, Rinke de Wit TF, Bertagnolio S. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1453\u201361. https:\/\/doi.org\/10.1093\/cid\/civ556.","DOI":"10.1093\/cid\/civ556"},{"key":"10858_CR62","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","volume":"380","author":"RK Gupta","year":"2012","unstructured":"Gupta RK, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet. 2012;380:1250\u20138.","journal-title":"Lancet"},{"key":"10858_CR63","unstructured":"UNAIDS. (2024, January 19). UNAIDS launches new approach to ensure the long-term sustainability of the HIV response. Retrieved from https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2024\/january\/20240119_HIV_response_sustainability_prime"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10858-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:59:30Z","timestamp":1745596770000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10858-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10858"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10858-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used previously published data and did not involve direct research with human participants or animals, thus ethical approval was not required according to institutional and national guidelines. All procedures followed the ethical standards of the responsible human experimentation committee and the Helsinki Declaration of 1975, revised in 2013. Any secondary data used was anonymized and accessed in compliance with data protection and privacy laws.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"604"}}